GlassScriptPhysician profile
Jonah S Marshall
NPI 1033223276
$5,120.73
in general payments reported to CMS, 2019-2025
39 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $469 · 2021: $541 · 2022: $409 · 2023: $732 · 2024: $1,547 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $674.13 | 2019-2022 | |
| Astellas Pharma US INC | $551.42 | 2019-2023 | Myrbetriq |
| Merck Sharp & Dohme LLC | $523.30 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Urogen Pharma, INC. | $491.48 | 2022-2025 | Jelmyto |
| Janssen Biotech, INC. | $338.01 | 2019-2025 | Erleada, Akeega, Balversa |
| Coloplast Corp | $251.90 | 2020-2025 | Speedicath |
| Boston Scientific Corporation | $233.86 | 2020-2024 | Rezum Generator, Ams 700 Cxr Rte Kit, Spaceoar Vue System - 10ml |
| Pfizer INC. | $221.36 | 2019-2025 | |
| Abbvie INC. | $218.81 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $217.75 | 2024 | Myrisk |
| Koelis INC. | $177.59 | 2024 | |
| Sumitomo Pharma America, INC. | $152.37 | 2023-2025 | Orgovyx, Gemtesa |
| Mimedx Group, INC. | $97.57 | 2024 | |
| Neotract INC. | $85.02 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.17 | 2019-2020 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $65.55 | 2020-2022 | |
| Alnylam Pharmaceuticals INC. | $57.97 | 2023-2024 | Givlaari |
| Dendreon Pharmaceuticals LLC | $57.41 | 2022-2025 | Provenge |
| Axonics, INC. | $55.39 | 2020-2024 | Axonics, Bulkamid |
| Olympus America INC. | $51.79 | 2023-2025 | Itind System |
| Procept Biorobotics Corporation | $46.59 | 2024-2025 | Aquabeam System |
| Amgen INC. | $46.42 | 2019 | |
| Allergan, INC. | $45.01 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $44.76 | 2021-2022 | |
| Tolmar, INC. | $43.75 | 2024 | |
| Teleflex LLC | $41.29 | 2024 | Urolift |
| Angiodynamics, INC. | $32.35 | 2022 | |
| Profound Medical Corp. | $29.94 | 2025 | Tulsa-Pro |
| Agiliti Surgical, INC. | $26.10 | 2023 | Sonablate |
| Ferring Pharmaceuticals INC. | $22.77 | 2024 | Adstiladrin |
| Dentsply Ih INC. | $19.82 | 2019 | |
| Antares Pharma, INC. | $18.16 | 2022 | |
| Halozyme INC | $16.33 | 2023 | |
| Accord Healthcare, INC. | $15.18 | 2024 | |
| Endo Pharmaceuticals INC. | $14.95 | 2021 | |
| Monaghan Medical Corporation | $13.49 | 2023 | Aeroeclipse |
| Myovant Sciences INC. | $13.32 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $11.88 | 2019 | |
| Metuchen Pharmaceuticals | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonah Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.